<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Broeders,N.E.</style></author><author><style face="normal" font="default" size="100%">Hombrouck,A.</style></author><author><style face="normal" font="default" size="100%">Lemy,A.</style></author><author><style face="normal" font="default" size="100%">Wissing,K.M.</style></author><author><style face="normal" font="default" size="100%">Racape,J.</style></author><author><style face="normal" font="default" size="100%">Gastaldello,K.</style></author><author><style face="normal" font="default" size="100%">Massart,A.</style></author><author><style face="normal" font="default" size="100%">Steven Van Gucht</style></author><author><style face="normal" font="default" size="100%">Weichselbaum,L.</style></author><author><style face="normal" font="default" size="100%">De Mul,A.</style></author><author><style face="normal" font="default" size="100%">Bernard Brochier</style></author><author><style face="normal" font="default" size="100%">Isabelle Thomas</style></author><author><style face="normal" font="default" size="100%">Abramowicz,D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study36521</style></title><secondary-title><style face="normal" font="default" size="100%">Clin.J.Am.Soc.Nephrol.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">2009</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">administration &amp; dosage</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">adverse effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Agent</style></keyword><keyword><style  face="normal" font="default" size="100%">Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">alpha-Tocopherol</style></keyword><keyword><style  face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style  face="normal" font="default" size="100%">antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies,Neutralizing</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies,Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibody</style></keyword><keyword><style  face="normal" font="default" size="100%">Antigens</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Brussels</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Chi-Square Distribution</style></keyword><keyword><style  face="normal" font="default" size="100%">Class</style></keyword><keyword><style  face="normal" font="default" size="100%">clinic</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort study</style></keyword><keyword><style  face="normal" font="default" size="100%">Combination</style></keyword><keyword><style  face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style  face="normal" font="default" size="100%">Control</style></keyword><keyword><style  face="normal" font="default" size="100%">data</style></keyword><keyword><style  face="normal" font="default" size="100%">Design</style></keyword><keyword><style  face="normal" font="default" size="100%">disease</style></keyword><keyword><style  face="normal" font="default" size="100%">DRUG</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style  face="normal" font="default" size="100%">electronic</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">GM</style></keyword><keyword><style  face="normal" font="default" size="100%">Histocompatibility Antigens Class I</style></keyword><keyword><style  face="normal" font="default" size="100%">Histocompatibility Antigens Class II</style></keyword><keyword><style  face="normal" font="default" size="100%">hospital</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">i</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style  face="normal" font="default" size="100%">immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunosuppressive Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">improve</style></keyword><keyword><style  face="normal" font="default" size="100%">Increase</style></keyword><keyword><style  face="normal" font="default" size="100%">INFLUENZA</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza A Virus,H1N1 Subtype</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza,Human</style></keyword><keyword><style  face="normal" font="default" size="100%">interval</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Failure,Chronic</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Luminex</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">measurement</style></keyword><keyword><style  face="normal" font="default" size="100%">measurements</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">objectives</style></keyword><keyword><style  face="normal" font="default" size="100%">ODDS RATIO</style></keyword><keyword><style  face="normal" font="default" size="100%">p</style></keyword><keyword><style  face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style  face="normal" font="default" size="100%">PARTICIPANTS</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient</style></keyword><keyword><style  face="normal" font="default" size="100%">patients</style></keyword><keyword><style  face="normal" font="default" size="100%">Polysorbates</style></keyword><keyword><style  face="normal" font="default" size="100%">POPULATION</style></keyword><keyword><style  face="normal" font="default" size="100%">Populations</style></keyword><keyword><style  face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style  face="normal" font="default" size="100%">prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">proportion</style></keyword><keyword><style  face="normal" font="default" size="100%">Ratio</style></keyword><keyword><style  face="normal" font="default" size="100%">Ratios</style></keyword><keyword><style  face="normal" font="default" size="100%">recommendation</style></keyword><keyword><style  face="normal" font="default" size="100%">Recommendations</style></keyword><keyword><style  face="normal" font="default" size="100%">regression analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">RENAL</style></keyword><keyword><style  face="normal" font="default" size="100%">Renal Dialysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Research</style></keyword><keyword><style  face="normal" font="default" size="100%">Research Support</style></keyword><keyword><style  face="normal" font="default" size="100%">response</style></keyword><keyword><style  face="normal" font="default" size="100%">result</style></keyword><keyword><style  face="normal" font="default" size="100%">results</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">serum</style></keyword><keyword><style  face="normal" font="default" size="100%">Squalene</style></keyword><keyword><style  face="normal" font="default" size="100%">study</style></keyword><keyword><style  face="normal" font="default" size="100%">surgery</style></keyword><keyword><style  face="normal" font="default" size="100%">technology</style></keyword><keyword><style  face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">virology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1/11/2011</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">2578</style></number><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">2573 - 2578</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVES: In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There are few data concerning the immunogenicity or the security of the adjuvanted-A/H1N1 vaccine in transplanted and hemodialyzed patients. DESIGN, SETTING, PARTICIPANTS, &amp; MEASUREMENTS: Sera from 21 controls, 53 hemodialyzed (HD) patients, and 111 renal transplant recipients (RT) were sampled before (T0) and 1 month after (T1) a single dose of Pandemrix(R) vaccine (GSK Biologicals, AS03-adjuvanted). We measured the neutralizing antibodies against A/H1N1/2009, the geometric mean (GM) titers, the GM titer ratios (T1/T0) with 95% confidence intervals, and the seroconversion rate (responders: &gt;/=4-fold increase in titer). The HLA and MICA immunization was determined by Luminex technology. RESULTS: The GM titer ratio was 38 (19 to 78), 9 (5 to 16), and 5 (3 to 6) for controls, HD patients, and RT patients, respectively (P &lt; 0.001). The proportion of responders was 90%, 57%, and 44%, respectively (P &lt; 0.001). In RT patients, the prevalence of histocompatibility leukocyte antigen (HLA) class I, histocompatibility leukocyte antigen class II, and MHC class I-related chain A immunization, was, respectively, 15%, 14%, and 14% before and 14%, 14%, and 11% after vaccination (P = 1, 1, and 0.39). CONCLUSIONS: The influenza A/H1N1-adjuvanted vaccine is of limited efficacy but is safe in renal disease populations. The humoral response is lower in transplanted versus hemodialyzed patients. Further studies are needed to improve the efficacy of vaccination in those populations</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">38093</style></custom1><section><style face="normal" font="default" size="100%">2573</style></section></record></records></xml>